Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, June 18, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, June 17, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Joseph Pantginis Reiterated (APRE) at Strong Buy and Held Target at $20 on, Jun 17th, 2024
Joseph Pantginis of HC Wainwright & Co., Reiterated "Aprea Therapeutics, Inc." (APRE) at Strong Buy and Held Target at $20 on, Jun 17th, 2024.
Joseph has made no other calls on APRE in the last 4 months.
There is 1 other peer that has a rating on APRE. Out of the 1 peers that are also analyzing APRE, 0 agree with Joseph's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joseph
- Robert Driscoll of "Wedbush" Maintained at Buy with Increased Target to $11 on, Wednesday, March 27th, 2024
